Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Bangkok Post - May 15, 2007
Previously, the firm planned to withhold sale of a heat-stable form of Aluvia, its HIV/Aids drug, as punishment for Thailand's compulsory licensing policy.
Representatives of Abbott made the company's stance known yesterday while meeting with Food and Drug Administration (FDA) secretary-general Siriwat Tiptaradol. The FDA also met with representatives from Sanofi-Aventis yesterday.
Abbott's new offer was made on condition that Thailand would not impose compulsory licensing on Aluvia and that the price of the drug, at 3,488.20 baht per person per month, or about 34,000 baht (US$1,000) per person per year, would not come down any further.
Dr Siriwat said the FDA would forward Abbott's offer to Public Health Minister Mongkol Na Songkhla. Abbott's Aluvia price will be compared with the prices quoted by India's generic drug maker, Matrix Laboratories, which produces a generic version of Aluvia at 24,324 baht (US$695) per person per year (or 2,027 baht per person per month).
Matrix made the offer to Thailand and 66 other countries which have agreed to purchase the generic drug, together with the US-based Clinton Foundation.
On the two-hour negotiations with Sanofi-Aventis which holds the patent for the heart disease drug Plavix, Dr Siriwat said the drug giant proposed a one-year project to give patients greater access to the medicine. During the one-year period, the firm would make available 3.4 million tablets of Plavix to 34,000 patients.
The scheme would automatically reduce Plavix's price from 90 baht to about 27 baht per tablet. The FDA will forward Sanofi-Aventis' offer to the health minister, said Dr Siriwat. He added that his committee will invite the pharmaceutical firms to discuss prices again on June 1.
Meanwhile, Vichai Chokewiwat, chairman of the Public Health Ministry's panel on compulsory licensing, said that if the Public Health Ministry chose to buy drugs at prices higher than offered by other sources, it must be able to give the public a good reason to justify its decision.
"If we buy the drug [the generic version of Aluvia] from India at US$695 per person per year, next time, we might get the drug at a lower price, probably as low as US$500. If we buy it from the US firm at US$1,000 now, we might have to continue buying it at US$1,000 forever."
070515
BP070510
Copyright © 2007 - The Bangkok Post. Reproduction of this article (other than one copy for personal reference) must be cleared through the Bangkok Post.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .